Tremfya carries a list price of roughly $20,000 or more per year, placing it alongside other high-cost biologic drugs. That price tag reflects a combination of factors: complex manufacturing, patent-protected exclusivity, the unusual economics of the U.S. drug rebate system, and an expanding set of approved uses that sustain demand.
What Tremfya Costs in Practice
Tremfya (guselkumab) is a biologic injection given once every eight weeks after an initial loading period. In Canada, where pricing data is publicly available through government reviews, a single 100 mg dose is priced at about $3,060 CAD, translating to roughly $20,000 to $21,000 CAD per year. U.S. list prices run higher, often cited in the range of $25,000 to $30,000 annually, though the exact figure shifts with annual price increases.
The “list price” is not what most people actually pay. It’s the sticker price before insurance negotiations, rebates, and discount programs. But it is the number that determines your copay or coinsurance percentage, which is why it matters even if you never see the full bill.
Biologics Are Expensive to Make
Tremfya is not a simple chemical pill. It’s a monoclonal antibody, a large protein grown inside living cells in carefully controlled bioreactors. Manufacturing biologics requires specialized facilities, extensive quality testing at every stage, and cold-chain storage from the factory to your refrigerator. A single contamination event can destroy an entire batch worth millions of dollars.
This is fundamentally different from producing a small-molecule drug like ibuprofen, where the active ingredient can be synthesized through straightforward chemical reactions and pressed into tablets on high-speed production lines. The cost floor for biologics is simply higher, and that baseline cost gets passed through to the final price.
Patent Protection Blocks Competition
Tremfya was first approved by the FDA in 2017 for moderate-to-severe plaque psoriasis. Since then, Janssen (a Johnson & Johnson company) has expanded its approved uses to include psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Each new indication can come with additional patent filings that extend the window of market exclusivity.
Without biosimilar competitors, there is no price pressure from rival manufacturers. For traditional drugs, generic versions typically drive prices down by 80% or more. Biosimilars, the biologic equivalent of generics, offer smaller discounts but still create meaningful competition. Until biosimilars for Tremfya reach the market, Janssen is the sole supplier and sets the price accordingly.
More Approved Uses Sustain the Price
Tremfya now carries four FDA-approved indications: plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Each approval required its own set of large clinical trials. The psoriatic arthritis approval alone involved at least three Phase 3 trials (DISCOVER-1, DISCOVER-2, and COSMOS), each enrolling hundreds of patients across multiple countries over several years.
These trials cost hundreds of millions of dollars collectively. Pharmaceutical companies price their drugs to recoup not just the cost of the successful product but also the cost of all the failed candidates that never made it to market. For every biologic that reaches patients, many more are abandoned during development. That accumulated R&D risk is baked into the price of the drugs that do succeed.
At the same time, each new indication expands the pool of potential patients, which helps justify sustaining a high price point. A drug approved for one rare condition has to charge more per patient than a drug prescribed to millions. Tremfya’s four indications give it a broad enough market to generate significant revenue at its current price.
The Rebate System Inflates List Prices
One of the less visible forces driving Tremfya’s sticker price is the rebate system that sits between drug manufacturers and insurance companies. Pharmacy benefit managers (PBMs) negotiate rebates on behalf of insurers, essentially collecting a discount from the manufacturer in exchange for favorable placement on insurance formularies.
Research from USC Schaeffer found that for branded drugs without generic competition, every $1 increase in rebates is associated with a $1.17 increase in list price. In other words, manufacturers raise their sticker prices roughly dollar-for-dollar to offset the rebates they pay out, keeping their net revenue relatively steady. The result is a system where the list price climbs year after year, but the net price the manufacturer actually receives stays fairly flat.
This matters because patients with coinsurance (where you pay a percentage of the drug’s cost rather than a flat copay) end up paying a percentage of the inflated list price, not the lower net price. The rebate savings flow to insurers and PBMs, not to the person picking up the prescription.
U.S. Prices Are Higher Than Other Countries
The United States does not regulate drug prices the way most other wealthy nations do. In Canada, government agencies like CADTH formally review whether a drug’s price is justified relative to its clinical benefit and negotiate reimbursement terms. The U.K., Germany, and Australia run similar processes. These systems create a ceiling on what manufacturers can charge.
In the U.S., manufacturers set their own list prices and negotiate individually with each insurer and PBM. This fragmented system consistently produces higher prices. The same dose of Tremfya that costs about $3,060 CAD in Canada (roughly $2,200 USD at typical exchange rates) carries a significantly higher list price in the American market. That gap exists not because the drug is different but because the pricing rules are different.
What You Might Actually Pay
Despite the high list price, many patients pay far less out of pocket. Janssen offers the TREMFYA withMe Savings Program for people with commercial (private) insurance, which can reduce the cost to as little as $0 per dose. The program covers both the cost of the medication itself and eligible administration costs like infusion fees and lab tests. No income verification is required to participate.
If you don’t have commercial insurance, the picture is more complicated. Medicare patients cannot use manufacturer copay cards due to federal rules, and Medicaid coverage varies by state. Janssen’s program can connect uninsured or publicly insured patients with other resources, but the support is less direct. For people who fall into these gaps, the full cost of Tremfya can be a genuine barrier to treatment.
The underlying economics are unlikely to change until biosimilar competition arrives. When it does, history with other biologics suggests prices could drop meaningfully, though biosimilar discounts tend to be more modest than what you see with traditional generic drugs.